On May 10, 2017 Roche (SIX: RO, ROG; OTCQX: RHHBY) reported new data on 20 approved and investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting from 2 June to 6 June in Chicago, United States (Press release, Hoffmann-La Roche, MAY 10, 2017, View Source [SID1234519024]). More than 190 abstracts have been accepted, including two "late breakers" and 24 oral presentations. Schedule your 30 min Free 1stOncology Demo! "We are making significant advances with personalised medicines and cancer immunotherapies," said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
With continued research and collaborations, we are striving to develop medicines and combinations, incorporate sophisticated diagnostics and integrate big data in our effort to get closer to the goal of curing cancer."
Key highlights from the Roche oncology portfolio include new results from the APHINITY study in early breast cancer and the ALEX study in lung cancer. Both of these studies will be highlighted as part of ASCO (Free ASCO Whitepaper)’s official press program on Monday 5 June. APHINITY is a randomised phase III study, investigating Perjeta plus Herceptin (trastuzumab) and chemotherapy as an adjuvant (after surgery) treatment for patients with HER2-positive early breast cancer.
The APHINITY study was conducted in collaboration with the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS). ALEX is a randomised, multicentre, open-label phase III study that compared Alecensa and crizotinib in people with previously untreated ALK-positive non-small cell lung cancer (NSCLC).
There has been great progress in the area of cancer immunotherapy in recent years and Roche continues to investigate novel ways to harness the immune system in the fight against cancer as part of its vision to bring the next generation of cancer immunotherapies to patients. With more than 20 investigational cancer immunotherapies in development and 12 in clinical trials, Roche will be presenting early results on its first T-cell bispecific antibody (CEA-CD3 TCB: RG7802; RO6958688) for the treatment of CEA-positive cancers, including metastatic colorectal cancer (mCRC). These data have been generated from two ongoing dose-escalation phase I studies in which CEA-CD3 TCB is used alone or in combination with TECENTRIQ (atezolizumab).
Further information on Roche’s contribution to the ASCO (Free ASCO Whitepaper) 2017 scientific program, as well as Roche’s wider progress in cancer care, will be featured during the Roche media briefing from 09:00–10:45 CDT on
Friday, 2 June at the Chicago Marriott Hotel Downtown Magnificent Mile.